Sprout Health Reviews: What the $199 Becomes, and the Verdict

The one-sentence version

Sprout Health sells one thing well: a single all-in NAD+ injection program with the clinician evaluation, the injection kit and expedited shipping inside one monthly figure and no minimum term. The figure is $249, not the $199 the site leads with — $199 buys the first month only — and it renews every four weeks, which is thirteen charges a year rather than twelve. It grades B, 10 points out of 14, and it is a paid partner here; the grade is computed from published terms alone and cannot see who pays us. It loses its points in one place, and it is not the price.

What Sprout Health is, and who it's for

Sprout Health is a LegitScript-certified telehealth practice operated by Sprout Health Partners LLC. Its longevity line is deliberately narrow — compounded NAD+ as a subcutaneous injection, sold as a single program rather than a menu — alongside a larger compounded GLP-1 business. You complete a medical intake, "a licensed provider will review your info and determine if NAD+ therapy is right for you — no clinic visit required," and if approved the prescription goes to a compounding pharmacy. Shipping is "free, discreet" and quoted at three to seven business days after approval.

There is no lab gate and no membership wrapper. That is genuinely the low-friction end of this category, and it suits a buyer who wants one route, one price and no diagnostic preamble. A buyer who wants baseline biomarkers before starting is in the wrong shop and should read longevity clinics versus lab memberships first.

What it actually costs, and what "$199" is doing

All figures verified on joinsprouthealth.com on 26 July 2026.

The headline and the real rate. The NAD+ page prices the monthly plan at "$199 / first month" then "$249 /mo after" for a 1,000 mg, 5 mL vial. The program page says it more directly: "$199 your first month, then auto renews at $249 every 4 weeks." So $199 is an introductory rate that steps up at the first refill, and $249 is what you actually pay from month two onward. To Sprout's credit, both pages state the step-up in plain language on their face — several competitors bury the equivalent in a policy document.

The four-week cadence is the part to do arithmetic on. "Every 4 weeks" is thirteen billing cycles in a year, not twelve. At $249 that is roughly $3,237 a year, about $249 more than the $2,988 that "per month" implies. No page states the annual figure.

There is a cheaper prepay tier. A three-month plan runs "$175 / first month" then "$225 /mo after" — about $24 a month less than the monthly plan, in exchange for paying up front. Unusually, leaving it is fair: the refund policy grants pro-rata refunds for unshipped months, and works the example — a $233.33-per-month plan value refunding $233.33 if you cancel after two of three shipments. That is a materially better multi-month exit than most of this board offers.

No minimum term. "No long-term contracts." Cancel whenever you like, subject to one tripwire below.

Cancel 48 hours early. "To avoid being charged for the next billing cycle, we need to receive your cancellation request at least 48 hours before your next scheduled billing date. Requests received after that window will take effect the following cycle, and the upcoming charge will still apply."

The free consult is conditional. The program page promises "free initial consultation: if you're not eligible, you pay nothing" — and that is true as written. What is also true, from the refund policy, is that once a provider has reviewed you and you change your mind before the prescription reaches the pharmacy, you get a "refund minus a flat $50 clinical review fee, reflecting the completed provider consultation." Being declined costs nothing; being approved and reconsidering costs $50. After the prescription reaches the pharmacy it is non-refundable, which is standard and lawful — dispensed medication cannot be restocked.

What's included, and what isn't

Included in $249: the clinician evaluation, the compounded NAD+ vial, "all supplies to get started right away" — syringes and alcohol wipes — and free expedited shipping. One figure, no add-ons, no membership.

Not included, and this is where the row loses points: no coaching, no dietitian time, no bundled human support beyond the care team, and no bloodwork at any stage. Nothing in the program measures whether the injections changed anything about you. For what such measurement would actually involve, see longevity biomarker panels.

Clinical oversight and the pharmacy

A licensed provider reviews every intake before anything ships, and that review is inside the price rather than billed separately — worth two of our fourteen points, and Sprout earns them.

The pharmacy is where it drops the rest. Sprout says its NAD+ is "compounded in the United States by state-licensed pharmacies" and elsewhere that they follow "strict pharmaceutical protocols." Neither statement classifies the facility, and no pharmacy is named. When its own press material was asked the question directly, it declined to answer: "Is the pharmacy state-licensed and operating under Section 503A or 503B of the FD&C Act? This varies by pharmacy and should be confirmed directly with the dispensing entity." Declining to classify is not a claim, so this factor scores zero — the same way it would for any row that said as little.

The distinction is not pedantry. A 503B outsourcing facility must follow current good manufacturing practice; a 503A compounding pharmacy specifically is not subject to those requirements¹. And either way, FDA is explicit: "compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"¹.

The FDA warning letter, in proportion

On 9 September 2025, FDA issued Sprout Health Partners LLC a warning letter (MARCS-CMS 715879) after reviewing joinsprouthealth.com. The citation is narrow and worth reading precisely: the site claimed "GLP-1 medications are FDA-approved and backed by extensive clinical research," which FDA found misbranded the company's compounded semaglutide and tirzepatide under sections 502(a) and 502(bb), because "compounded drug products are not FDA-approved" and the wording implied equivalence with approved products².

That is a marketing and labelling action. The letter alleges no patient harm, no adverse event, no manufacturing or sterility finding, and it concerns the GLP-1 line rather than NAD+. It belongs in this review because it is a real regulatory record on the operating entity, and it belongs in one paragraph rather than a headline because inflating it would misdescribe what FDA actually said.

The evidence behind what it sells

Sprout sells NAD+ as energy, recovery and "age reversal." The literature does not carry that.

The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies, 33 of them human intervention trials. Oral nicotinamide riboside and NMN reliably engage the target — blood NAD+ rises³ — and are well tolerated, but effects on functional, metabolic and vascular outcomes were "heterogeneous and often null or endpoint-specific," and clinical effectiveness for anti-aging or wellness "remains inconclusive"⁴. The review is blunter still about injected NAD+: "no eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications"⁴. Sprout sells exactly one route, and it is the route with no outcome trials behind it.

The strongest randomised trial in the field moved six-minute walk distance by roughly 17.6 metres in peripheral artery disease — a disease endpoint, not an aging one⁵. A separate systematic review of NAD and NADH across ten randomised trials in 489 participants found supplementation well tolerated with no serious safety signal, and outcomes scattered across unrelated conditions rather than converging on healthspan⁶. No completed human trial shows NAD+ repletion improves cognition, energy or the rate of aging. See NAD+ for longevity, do NAD+ peptides actually work and what's proven versus hyped.

Where it's weak, and who should skip it

Skip Sprout if you want to know which pharmacy standard applies to your vial — it will not tell you, and it has said so in writing. Skip it if you want coaching, follow-up or any measurement of effect; this is a dispensing program, not a care program. Skip it if $249 every four weeks for a single injectable route looks expensive next to the board, because it is at the top of the month-to-month range.

If you proceed, do three things: budget $249 rather than $199, budget thirteen cycles rather than twelve, and set a reminder 48 hours before each billing date.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), whether the provider sells real longevity medicine (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Sprout takes the full four for price transparency — one all-in published figure, no membership, no prepay required to reach it, and the step-up disclosed on the page rather than buried. It takes four for a genuine longevity line and two for a clinician review inside the price. It takes zero for pharmacy, because it explicitly declines to state the standard, and zero for support, because nothing beyond the care team is bundled. Ten of fourteen. A B.

That is a fair reflection of what it is: an honest, narrow, slightly expensive program that tells you almost everything except who makes the drug. The price is not the criticism — the criticism is that a company willing to publish a real recurring rate, a real cancellation window and a pro-rata multi-month refund is also willing to send you to the pharmacy for an answer it could give itself. Naming the facility and its section would move this row up. The full graded field is at our provider rankings, the scoring is set out in how we grade, and two neighbours are in our Enhance MD review and Shed review.